None
DE
Silence Therapeutics plc: Silence Therapeutics Announces Pricing of Upsized $175 Million Underwritten Public Offering
['Business Wire']
FinanzNachrichten.de: News
In addition, Silence has granted the underwriters a 30-day option to purchase up to an additional 1,944,444 ADSs at the public offering price, less the underwriting discounts and commissions.
This press release must not be acted on or relied on in any EEA member state by persons who are not Qualified Investors.
Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.
All statements in this press release other than statements of historical facts are "forward-looking statements."
Forward-looking statements in this press release include, but are not limited to, statements concerning the public offering, expected proceeds from the proposed offering, and expected closing of the proposed offering.